Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Perry who wrote (2061)	6/29/1998 4:18:00 PM
From: JMarcus	Respond to of 4676

Friday's Daily Interpreter of Westergaard Abella BioMedtech Online predicted Advisory Committee disapproval of Formivirsen, primarily because ISIP's stock price had been in a downward trend and market behavior prior to an FDA decision is highly predictive of what that decision will be. westergaard.com:8080/Med/MEDPE/1998/weekof98062226/fri.htm If today's resurgence in ISIP's stock price continues, Abella will have to reverse his prediction. I hope so. I'm not long ISIP, but I am long two other antisense companies: GNTA and HYBN. The verdict on Formivirsen is likely to have repercussions for them as well.